,pmid,title,author,pubdate,keywords,prob,pmcid,table_info
0,31610099,"Bioequivalence Study of 2 Formulations of Rivaroxaban, a Narrow-Therapeutic-Index Drug, in Healthy Chinese Subjects Under Fasting and Fed Conditions.",S Ding; L Wang; L Xie; S Zhou; J Chen; Y Zhao; W Deng; Y Liu; H Zhang; F Shao,2020,bioequivalence; narrow-therapeutic-index drug; pharmacokinetic; rivaroxaban,0.9992654919624329,,
1,18715524,Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.,D Kubitza; M Becka; A Roth; W Mueck,2008,,0.9989181756973267,,
2,17595891,"Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.",W Mueck; M Becka; D Kubitza; B Voith; M Zuehlsdorf,2007,,0.9988715052604675,,
3,25419161,A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.,C Frost; Y Song; YC Barrett; J Wang; J Pursley; RA Boyd; F LaCreta,2014,apixaban; pharmacodynamics; pharmacokinetics; rivaroxaban; safety,0.998711347579956,PMC4235474,"PK - Table 2, Table 3 | Study Population - Table 1"
4,27100875,"Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.",C Dias; KT Moore; J Murphy; J Ariyawansa; W Smith; RM Mills; MR Weir,2016,,0.9985791444778442,,
5,21039764,"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.",D Kubitza; M Becka; W Mueck; A Halabi; H Maatouk; N Klause; V Lufft; DD Wand; T Philipp; H Bruck,2010,,0.9984368681907654,PMC2997310,
6,18766262,Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.,W Mueck; LC Borris; OE Dahl; S Haas; MV Huisman; AK Kakkar; P Kälebo; E Muelhofer; F Misselwitz; BI Eriksson,2008,,0.9984055161476135,,
7,28121368,Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.,D Kröll; G Stirnimann; A Vogt; DLL Lai; YM Borbély; J Altmeier; S Schädelin; D Candinas; L Alberio; PC Nett,2017,Roux-en-Y gastric bypass; anticoagulation; bariatric surgery; pharmacodynamics; rivaroxaban; sleeve gastrectomy,0.998313307762146,PMC5465330,
8,23294275,"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.",D Kubitza; A Roth; M Becka; A Alatrach; A Halabi; H Hinrichsen; W Mueck,2013,,0.9982977509498596,PMC3703231,
9,16308283,"Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs.",C Weinz; U Buetehorn; HP Daehler; C Kohlsdorfer; U Pleiss; S Sandmann; KH Schlemmer; T Schwarz; W Steinke,2005,,0.9978214502334595,,
10,29127863,Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study.,YW Cheung; S Barco; RAA Mathôt; EJ van den Dool; AK Stroobants; MJ Serlie; S Middeldorp; M Coppens,2017,Anticoagulants; Dabigatran etexilate; Parenteral nutrition; Pharmacokinetics; Rivaroxaban; Short bowel syndrome,0.9977250695228577,,
11,32633174,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats.,J Chong; H Chen; D Dai; S Wang; Q Zhou; J Liu; Y Lü; H Wu; M Du; F Chen; H Jiang; Y Zhou; J Yang,2020,Anticoagulation; UPLC-MS/MS; atrial fibrillation; drug–drug interaction; rat liver microsomes,0.9976189732551575,PMC7470163,PK - Table 1 | Study Population - None
12,19660005,"Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.",X Zhao; P Sun; Y Zhou; Y Liu; H Zhang; W Mueck; D Kubitza; RJ Bauer; H Zhang; Y Cui,2009,,0.9973961114883423,PMC2732942,
13,20062915,"Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.",J Jiang; Y Hu; J Zhang; J Yang; W Mueck; D Kubitza; RJ Bauer; L Meng; P Hu,2010,,0.9973270893096924,,
14,30534007,"Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study.",D Kubitza; S Willmann; M Becka; K Thelen; G Young; LR Brandão; P Monagle; C Male; A Chan; G Kennet; I Martinelli; P Saracco; AWA Lensing,2018,Developmental hemostasis; Pharmacodynamics; Pharmacokinetics; Rivaroxaban; Venous thromboembolism,0.9967948794364929,PMC6278122,
15,23458226,The effect of food on the absorption and pharmacokinetics of rivaroxaban.,J Stampfuss; D Kubitza; M Becka; W Mueck,2013,,0.9967807531356812,,
16,34366151,Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.,V Russo; D Cattaneo; L Giannetti; R Bottino; N Laezza; U Atripaldi; E Clementi,2021,DOACs; atrial fibrillation; obesity; pharmacokinetics,0.9962490200996399,,
17,32959922,Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans.,I Scholz; E Liakoni; F Hammann; KE Grafinger; U Duthaler; M Nagler; S Krähenbühl; M Haschke,2021,CYP3A4; Hypericum perforatum; P-glycoprotein; St John's wort; cytochrome P450; drug interaction; phenotyping; rivaroxaban,0.9957946538925171,,
18,16198660,"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.",D Kubitza; M Becka; B Voith; M Zuehlsdorf; G Wensing,2005,,0.9957665205001831,,
19,23381840,"The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.",D Kubitza; M Becka; A Roth; W Mueck,2013,,0.9956068396568298,,
20,27599304,Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats.,AC Dixon-Jimenez; BM Brainard; MB Brooks; B Nie; RD Arnold; D Loper; JC Abrams; GS Rapoport,2016,anticoagulant therapy; feline; hemostasis; oral FXa inhibitor,0.9947466254234314,,
21,26597179,Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.,DA Parasrampuria; D Weilert; JF Maa; V Dishy; J Kochan; M Shi; KS Brown,2016,,0.9938862919807434,PMC4740573,
22,25804678,Dose-finding study of rivaroxaban in hemodialysis patients.,AS De Vriese; R Caluwé; E Bailleul; D De Bacquer; D Borrey; B Van Vlem; SJ Vandecasteele; J Emmerechts,2015,Hemodialysis; anti-FXa activity; anticoagulant; area under the curve (AUC); atrial fibrillation; dose adjustment; dose finding; dosing guideline; end-stage renal disease (ESRD); pharmacodynamics; pharmacokinetics; rivaroxaban; stroke,0.9934852719306946,,
23,30725221,Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study.,J Zdovc; M Petre; M Pišlar; K Repnik; A Mrhar; M Vogrin; U Potočnik; I Grabnar,2019,ABCB1 expression; Orthopedic surgery; Population pharmacokinetics/pharmacodynamics; Rivaroxaban,0.9932209253311157,,
24,16638738,"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.",D Kubitza; M Becka; M Zuehlsdorf; W Mueck,2006,,0.9931285381317139,,
25,32246743,Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation.,G Young; AWA Lensing; P Monagle; C Male; K Thelen; S Willmann; JS Palumbo; R Kumar; I Nurmeev; K Hege; F Bajolle; P Connor; HL Hooimeijer; M Torres; AKC Chan; G Kenet; S Holzhauer; A Santamaría; P Amedro; J Beyer-Westendorf; I Martinelli; MP Massicotte; WT Smith; SD Berkowitz; S Schmidt; V Price; MH Prins; D Kubitza; ,2020,anticoagulation; bodyweight-adjusted dosing; pediatric patients; pharmacokinetics; rivaroxaban; suspension; venous thromboembolism,0.9928784966468811,,
26,21895039,Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.,W Mueck; AW Lensing; G Agnelli; H Decousus; P Prandoni; F Misselwitz,2011,,0.9927310347557068,,
27,16328318,"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.",D Kubitza; M Becka; G Wensing; B Voith; M Zuehlsdorf,2005,,0.9927067160606384,,
28,30151746,Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study.,S Zheng; SB Luo; YB Mei; J Guo; LJ Tong; Q Zhang; XY Ye,2019,,0.9921591281890869,,
29,30534008,Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study.,S Willmann; K Thelen; D Kubitza; AWA Lensing; M Frede; K Coboeken; J Stampfuss; R Burghaus; W Mück; J Lippert,2018,Pediatric; Pharmacokinetics; Physiologically based pharmacokinetic modelling; Rivaroxaban,0.9917232394218445,PMC6278136,
30,21822144,"Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.",KT Moore; AN Plotnikov; A Thyssen; N Vaccaro; J Ariyawansa; PB Burton,2011,,0.9908050298690796,,
31,30216091,"Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.",M Yamazaki-Nishioka; M Kogiku; M Noda; S Endo; M Takekawa; H Kishi; M Ota; Y Notsu; M Shimizu; H Yamazaki,2019,Anticoagulants; insufficient dose; overdose; pharmacokinetic modeling; renal impairment,0.9907519817352295,,
32,29660785,Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.,S Willmann; L Zhang; M Frede; D Kubitza; W Mueck; S Schmidt; A Solms; X Yan; D Garmann,2018,,0.9905315637588501,PMC5980303,
33,27511836,"Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers.",HY Choi; S Choi; YH Kim; HS Lim,2016,,0.9882475733757019,PMC5080649,PK - Table 2 | Study Population - Table 1
34,31898270,Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect.,MK Anwer; M Mohammad; M Iqbal; MN Ansari; E Ezzeldin; F Fatima; SM Alshahrani; MF Aldawsari; A Alalaiwe; AA Alzahrani; AM Aldayel,2020,Bioavailability; Food effect; Nanoparticles; PLGA; Rivaroxaban,0.988081693649292,,
35,33143037,Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban.,LT Ngo; SY Yang; QT Tran; SK Kim; HY Yun; JW Chae,2020,carbamazepine; drug interaction; pharmacodynamics; pharmacokinetics; phenytoin; rivaroxaban,0.9864329695701599,PMC7693231,"PK - Table 1, Table 4 | Study Population - None"
36,34256392,Pharmacokinetics of direct oral anticoagulants in emergency situations - Results of the prospective observational RADOA-registry.,E Lindhoff-Last; I Birschmann; J Kuhn; S Lindau; S Konstantinides; O Grottke; U Nowak-Göttl; J Lucks; B Zydek; C von Heymann; A Sümnig; J Beyer-Westendorf; S Schellong; P Meybohm; A Greinacher; E Herrmann,2021,,0.9855389595031738,PMC9113852,PK - None | Study Population - Table 1
37,27893182,Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.,I Gouin-Thibault; X Delavenne; A Blanchard; V Siguret; JE Salem; C Narjoz; P Gaussem; P Beaune; C Funck-Brentano; M Azizi; P Mismetti; MA Loriot,2017,P-gp transporter; anticoagulant; drug interactions; pharmacogenetics; pharmacokinetics,0.9853519797325134,,
38,29637496,Preparation and Optimization of Rivaroxaban by Self-Nanoemulsifying Drug Delivery System (SNEDDS) for Enhanced Oral Bioavailability and No Food Effect.,X Xue; M Cao; L Ren; Y Qian; G Chen,2018,LC-MS; SNEDDS; central composite design; no food effect; rivaroxaban,0.9842817187309265,,
39,30912163,Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.,A Brings; ML Lehmann; KI Foerster; J Burhenne; J Weiss; WE Haefeli; D Czock,2019,ciclosporin; cytochrome P450 CYP3A; drug-drug interaction; fluconazole; midazolam; pharmacokinetics; rivaroxaban,0.9841614961624146,PMC6595291,
40,27910037,Effect of Activated Charcoal on Rivaroxaban Complex Absorption.,E Ollier; S Hodin; J Lanoiselée; J Escal; S Accassat; E De Magalhaes; T Basset; L Bertoletti; P Mismetti; X Delavenne,2017,,0.983930766582489,,
41,28805299,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.,R Kreutz; PB Persson; D Kubitza; K Thelen; S Heitmeier; S Schwers; M Becka; M Hemmrich,2017,activated partial thromboplastin time; apixaban; direct factor Xa inhibitors; prothrombin time; rivaroxaban; thrombin generation,0.9837257266044617,,
42,22242932,Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.,XS Xu; K Moore; P Burton; K Stuyckens; W Mueck; S Rossenu; A Plotnikov; M Gibson; A Vermeulen,2012,,0.9833364486694336,PMC3394132,
43,20947383,Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.,M Gheorghiade; A Thyssen; R Zolynas; VK Nadar; BH Greenberg; M Mehra; X Sun; H Tian; AN Plotnikov; P Burton,2011,,0.9827213883399963,,
44,33356742,Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation.,MK Elsayad; HA Mowafy; AA Zaky; AM Samy,2021,Rivaroxaban; chitosan-coated liposomes; flexible liposomes,0.9821380376815796,,
45,23912563,Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.,S Willmann; C Becker; R Burghaus; K Coboeken; A Edginton; J Lippert; HU Siegmund; K Thelen; W Mück,2014,,0.9812982082366943,PMC3889826,
46,31184800,Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy.,M Galli; D D'Amario; F Andreotti; I Porto; R Vergallo; M Sabatelli; S Lancellotti; E Meleo; R De Cristofaro; F Crea,2019,Amyotrophic lateral sclerosis; Atrial fibrillation; Edoxaban; Percutaneous endoscopic gastrostomy; Takotsubo syndrome,0.9810957312583923,PMC6676270,
47,29194698,Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.,DJ Greenblatt; M Patel; JS Harmatz; WT Nicholson; CM Rubino; CR Chow,2018,Factor Xa inhibitor; bleeding risk; drug interactions; renal insufficiency; rivaroxaban; verapamil,0.9809819459915161,,
48,31514543,Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study.,K Shaikh; A Mungantiwar; S Halde; N Pandita,2020,Rivaroxaban; bioavailability; bioequivalence; liquid chromatography/tandem mass spectrometry; pharmacokinetics,0.9798123836517334,,
49,18307374,"Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.",W Mueck; BI Eriksson; KA Bauer; L Borris; OE Dahl; WD Fisher; M Gent; S Haas; MV Huisman; AK Kakkar; P Kälebo; LM Kwong; F Misselwitz; AG Turpie,2008,,0.9791394472122192,,
50,32007354,Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.,E Goto; S Horinaka; T Ishimitsu; T Kato,2020,Apixaban; Atrial fibrillation; Edoxaban; Plasma concentration; Population pharmacokinetics; Rivaroxaban; Venous thromboembolism; anti-FXa activity,0.9729199409484863,,
51,30046688,The impact of body weight on rivaroxaban pharmacokinetics.,SJ Barsam; JP Patel; LN Roberts; V Kavarthapu; RK Patel; B Green; R Arya,2017,anticoagulation; obesity; pharmacokinetics; rivaroxaban; weight,0.9705552458763123,PMC6058267,
52,24668660,Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.,IG Girgis; MR Patel; GR Peters; KT Moore; KW Mahaffey; CC Nessel; JL Halperin; RM Califf; KA Fox; RC Becker,2014,anticoagulants/administration and dosage; anticoagulants/pharmacokinetics; atrial fibrillation/drug therapy; humans; rivaroxaban PK/PD,0.9673359990119934,,
53,31845601,LC-MS/MS method for simultaneous determination of rivaroxaban and metformin in rat plasma: application to pharmacokinetic interaction study.,S Gai; A Huang; T Feng; N Gou; X Wang; C Lu; H Tang; D Xu; B Zhang; L Wang,2019,LC–MS/MS; metformin; pharmacokinetic interactions; rivaroxaban,0.9666823148727417,,
54,23999929,Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.,W Mueck; J Stampfuss; D Kubitza; M Becka,2014,,0.9654511213302612,PMC3889701,"PK - Table 1, Table 3 | Study Population - None"
55,33885176,Sensitive LC-MS/MS method for quantification of rivaroxaban in plasma: Application to pharmacokinetic studies.,AC de Oliveira; MG Davanço; DR de Campos; PHG Sanches; JPG Cirino; PO Carvalho; MA Antônio; EC Coelho; AM Porcari,2021,LC-MS/MS; bioanalytical method; pharmacokinetics; rivaroxaban; validation,0.9651543498039246,,
56,30893910,Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban.,M Kim; H Son; K Noh; E Kim; BS Shin; W Kang,2019,PK/PD modeling; drug–drug interaction; prothrombin time; rivaroxaban; verapamil,0.9643714427947998,PMC6470838,"PK - Table 1, Table 3 | Study Population - None"
57,32511863,Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis.,V Speed; B Green; LN Roberts; S Woolcombe; J Bartoli-Abdou; S Barsam; R Byrne; E Gee; J Czuprynska; A Brown; S Duffy; B Vadher; R Patel; V Scott; A Gazes; RK Patel; R Arya; JP Patel,2020,anticoagulants; body weight; drug monitoring; pharmacokinetics; rivaroxaban,0.9620065093040466,,
58,32767034,Assessment of Dose Proportionality of Rivaroxaban Nanocrystals.,H Demir; T Gulsun; MH Ozkan; E Nemutlu; S Sahin; L Öner,2020,dissolution rate; dose proportionality; nanocrystals; pharmacokinetics; rivaroxaban,0.9594497084617615,,
59,24281379,"Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study.",D Kubitza; M Becka; W Mück; S Schwers,2012,,0.9593896865844727,PMC3763640,PK - Table 1 | Study Population - None
60,31849262,Simultaneous determination of Rivaroxaban and TAK-438 in rat plasma by LC-MS/MS: application to pharmacokinetic interaction study.,L Wang; S Gai; X Zhang; X Xu; N Gou; X Wang; N Zhou; T Feng,2020,LC–MS/MS; TAK-438; pharmacokinetic interactions; rivaroxaban,0.9573403000831604,,
61,30411284,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study.,KK Viktil; I Lehre; AH Ranhoff; E Molden,2019,,0.9545273780822754,,
62,34292671,Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions.,S Willmann; K Coboeken; Y Zhang; H Mayer; I Ince; E Mesic; K Thelen; D Kubitza; AWA Lensing; H Yang; P Zhu; W Mück; HJ Drenth; J Lippert,2021,,0.9504715204238892,PMC8520753,PK - TABLE 2 | Study Population - None
63,25475601,Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.,KT Moore; W Byra; S Vaidyanathan; J Natarajan; J Ariyawansa; H Salih; KC Turner,2015,pharmacodynamic; pharmacokinetic; rivaroxaban; switching; warfarin,0.9499913454055786,PMC4456123,PK - Table 2 | Study Population - Table 1
64,33752054,HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies.,T Elawady; A Khedr; N El-Enany; F Belal,2021,Erdafitinib; HPLC; Mouse plasma; Pharmacokinetic,0.947733461856842,,
65,19196845,"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.",C Weinz; T Schwarz; D Kubitza; W Mueck; D Lang,2009,,0.9450097680091858,,
66,31215111,Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.,V Siguret; J Abdoul; X Delavenne; E Curis; A Carlo; A Blanchard; JE Salem; P Gaussem; C Funck-Brentano; M Azizi; P Mismetti; MA Loriot; T Lecompte; I Gouin-Thibault,2019,healthy volunteers; pharmacodynamic model; rivaroxaban; thrombin generation; thrombomodulin,0.9442775845527649,,
67,24964176,"An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.",KT Moore; S Vaidyanathan; J Natarajan; J Ariyawansa; L Haskell; KC Turner,2014,drug-drug-disease interaction; erythromycin; pharmacokinetics; renal impairment; rivaroxaban,0.9437921643257141,PMC4241044,"PK - Table 2, Table 3, Table 4 | Study Population - Table 1"
68,31276324,Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.,A Solms; M Frede; SD Berkowitz; A Hermanowski-Vosatka; D Kubitza; W Mueck; TE Spiro; S Willmann; X Yan; L Zhang; D Garmann,2019,,0.9410118460655212,PMC6875705,PK - Table 2 | Study Population - None
69,30192025,Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.,A Huppertz; L Werntz; AD Meid; KI Foerster; J Burhenne; D Czock; G Mikus; WE Haefeli,2018,Saint John's wort; macitentan; pharmacokinetic interaction; rivaroxaban,0.9401998519897461,PMC6255992,
70,25479967,Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan.,T Okata; K Toyoda; A Okamoto; T Miyata; K Nagatsuka; K Minematsu,2014,,0.9401874542236328,PMC4257912,
71,29572341,In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein.,V Margelidon-Cozzolino; S Hodin; E Jacqueroux; O Delézay; L Bertoletti; X Delavenne,2018,,0.9358649849891663,,
72,29192518,In vitro dissolution method fitted to in vivo absorption profile of rivaroxaban immediate-release tablets applying in silico data.,NR Wingert; NO Dos Santos; SC Campanharo; ES Simon; NM Volpato; M Steppe,2018,Rivaroxaban; dissolution; in silico data; in vitro–in vivo relationship; method validation,0.9300776124000549,,
73,29239000,Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.,M Ismail; VH Lee; CR Chow; CM Rubino,2018,drug-disease interaction; drug-drug interaction; physiologically based pharmacokinetic model; renal impairment; rivaroxaban; verapamil,0.9300463795661926,,
74,30349887,Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study.,S Piran; H Traquair; N Chan; V Bhagirath; S Schulman,2018,anticoagulants; laboratories; obesity; pharmacology; thrombosis,0.9235969185829163,PMC6178753,
75,24528331,Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.,D Kubitza; M Becka; W Mück; J Krätzschmar,2014,international normalized ratio; pharmacodynamics; prothrombin time; rivaroxaban; therapy transition; warfarin,0.9222432971000671,PMC4137827,PK - Table 3 | Study Population - Table 1
76,33205449,Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.,S Willmann; K Coboeken; S Kapsa; K Thelen; M Mundhenke; K Fischer; B Hügl; W Mück,2021,drug-drug interaction; hepatic impairment; pharmacokinetics; physiologically based pharmacokinetic modeling; renal impairment; rivaroxaban,0.9143773913383484,PMC8048900,PK - None | Study Population - None
77,19351271,"Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty.",LC Borris,2009,,0.9089009761810303,,
78,29376194,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.,MHJ Wiesen; C Blaich; M Taubert; V Jennissen; T Streichert; R Pfister; G Michels,2018,Anti-Xa assay; Cardiac catheterization; Discontinuation; Mass spectrometry; Oral anticoagulation; Rivaroxaban,0.9053708910942078,,
79,26842561,Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.,J Beyer; T Trujillo; S Fisher; A Ko; SE Lind; TH Kiser,2016,anticoagulants; clinical pharmacology; factor Xa inhibitors,0.9033551216125488,,
80,31617197,"Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.",D Sychev; R Minnigulov; P Bochkov; K Ryzhikova; I Yudina; A Lychagin; T Morozova,2019,Drug concentration; Gene polymorphisms; P-glycoprotein; Pharmacogenetics; Rivaroxaban; Thromboprophylaxis,0.9025876522064209,,
81,24861792,"Direct oral anticoagulants--pharmacology, drug interactions, and side effects.",CE Dempfle,2014,,0.8990461826324463,,
82,25240443,Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.,A Safouris; A Demulder; N Triantafyllou; G Tsivgoulis,2014,,0.8957930207252502,,
83,27121789,Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects.,D Kubitza; M Becka; S Schwers; B Voith,2013,enoxaparin; pharmacodynamics; pharmacokinetics; rivaroxaban,0.8930615782737732,,
84,33800741,The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers.,JH Lee; HS Jeong; JW Jeong; TS Koo; DK Kim; YH Cho; GW Lee,2021,amorphous solid dispersion (ASD); bioavailability; hot-melt extruding technique; quality by design (QbD); rivaroxaban (RXB),0.8920025825500488,PMC8001048,PK - Table 6 | Study Population - None
85,30859645,Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time.,J Bae; H Kim; W Kim; S Kim; J Park; DI Jung; D Yu,2019,TEG; anti-Xa; oral anticoagulant; point-of-care PT test,0.8788200616836548,PMC6524124,
86,28682477,Preclinical safety and efficacy of andexanet alfa in animal models.,G Lu; SJ Hollenbach; DC Baker; S Tan; A Hutchaleelaha; JT Curnutte; PB Conley,2017,andexanet; antidote; biomarker; bleeding; factor Xa inhibitor; recombinant protein,0.8720859885215759,,
87,25179681,"Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.",T Xue; S Ding; B Guo; Y Zhou; P Sun; H Wang; W Chu; G Gong; Y Wang; X Chen; Y Yang,2014,,0.8672487735748291,,
88,33672439,"On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet.",V Kushwah; S Arora; M Tamás Katona; D Modhave; E Fröhlich; A Paudel,2021,BCS Class II; Rivaroxaban; Xarelto; food effect; in vitro–in vivo correlation; physiologically based pharmacokinetic model; population kinetics,0.8656840324401855,PMC7923293,"PK - Table 3, Table 5, Table 6, Table 7, Table 8, Table 9 | Study Population - None"
89,17244773,"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.",D Kubitza; M Becka; M Zuehlsdorf; W Mueck,2007,,0.8583041429519653,,
90,23305158,Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.,W Mueck; D Kubitza; M Becka,2013,P-glycoprotein; cytochrome P450; drug interactions; healthy subjects; rivaroxaban,0.8505105972290039,PMC3769672,
91,23417780,Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.,A Mahlmann; S Gehrisch; J Beyer-Westendorf,2013,,0.8494617342948914,,
92,27128839,Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube.,KT Moore; MA Krook; S Vaidyanathan; TC Sarich; CV Damaraju; LE Fields,2014,bioavailability; factor Xa inhibitor; nasogastric tube; pharmacokinetics; rivaroxaban,0.8438319563865662,,
93,19712596,[Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].,JP Ordovás Baines; E Climent Grana; A Jover Botella; I Valero García,2009,,0.8402972221374512,,
94,30828771,Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.,G Mikus; KI Foerster; M Schaumaeker; ML Lehmann; J Burhenne; WE Haefeli,2019,,0.8374788761138916,,
95,19185782,[Rivaroxaban: clinical pharmacology].,P Mismetti; S Laporte,2008,,0.8268136382102966,,
96,32438078,"Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation.",G Camporese; D Bernardi; E Bernardi; GP Avruscio; F Marchini; L Bonfante; L Furian; F Neri; S Villalta; F Fabris; P Simioni; MT Sartori,2020,Immunosuppressants; Pharmacokinetics; Renal transplantation; Rivaroxaban; Venous thromboembolism,0.8231912851333618,,
97,33107158,The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs.,AM Lynch; LK Ruterbories; E Griffith; RM Hanel; AP Stablein; MB Brooks,2021,anticoagulant; antithrombotic; canine direct oral anticoagulants; thromboembolism,0.8228800296783447,,
98,23809871,"Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring.",W Mueck; S Schwers; J Stampfuss,2013,,0.8195756673812866,PMC3726366,"PK - Table 1, Table 3 | Study Population - None"
99,33650251,Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment.,V Speed; LN Roberts; R Arya; JP Patel,2021,,0.8125206828117371,,
100,26672898,Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics.,S Testa; A Tripodi; C Legnani; V Pengo; R Abbate; C Dellanoce; P Carraro; L Salomone; R Paniccia; O Paoletti; D Poli; G Palareti; ,2016,Anti-FXa; Creatinine clearance; DOAC; Dilute thrombin time; Inter-individual variability; Intra-individual variability,0.8105127811431885,,
101,28066243,Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.,K Ing Lorenzini; Y Daali; P Fontana; J Desmeules; C Samer,2016,ABCB1; CYP3A4/5; adverse drug reaction; direct oral anticoagulants; drug-drug interaction; genetic polymorphism,0.8074297904968262,PMC5165251,PK - None | Study Population - None
102,29773500,An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1).,S Suzuki; T Yamashita; H Kasai; T Otsuka; K Sagara,2018,Anticoagulation; Atrial fibrillation; Population pharmacokinetics; Prothrombin time; Rivaroxaban; Serum concentration,0.8064855933189392,,
103,29453492,Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.,R Xu; W Ge; Q Jiang,2018,Drug-drug interaction; Hepatic dysfunction; Physiologically based pharmacokinetic model; Renal dysfunction; Rivaroxaban,0.8026971220970154,,
104,21848931,Pharmacodynamic and pharmacokinetic basics of rivaroxaban.,R Kreutz,2012,,0.7958816289901733,,
105,16920892,"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.",D Kubitza; M Becka; W Mueck; M Zuehlsdorf,2006,,0.7946914434432983,,
106,17334516,"Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.",BJ Biemond; E Perzborn; PW Friederich; M Levi; U Buetehorn; HR Büller,2007,,0.779201328754425,,
107,20139357,Rivaroxaban: a new oral factor Xa inhibitor.,E Perzborn; S Roehrig; A Straub; D Kubitza; W Mueck; V Laux,2010,,0.7737879157066345,,
108,17873238,"Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.",J Graff; N von Hentig; F Misselwitz; D Kubitza; M Becka; HK Breddin; S Harder,2007,,0.7726180553436279,,
109,28167637,Rivaraoxaban dosing is based on more than just pharmacokinetic properties.,A Aggarwal,2017,,0.7699267864227295,,
110,22813718,Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation.,T Tanigawa; M Kaneko; K Hashizume; M Kajikawa; H Ueda; M Tajiri; JF Paolini; W Mueck,2013,,0.7650818824768066,,
111,27105920,A highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample.,M Iqbal,2016,Pharmacokinetics; Plasma; Tedizolid; UPLC-MS/MS,0.7541061043739319,,
112,18675600,"Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.",G Rohde,2008,,0.7518835067749023,,
113,29614520,Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients.,A Kaserer; A Schedler; A Jetter; B Seifert; DR Spahn; P Stein; JD Studt,2018,,0.7482279539108276,,
114,32323192,Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.,L Zhang; X Yan; KAA Fox; S Willmann; P Nandy; SD Berkowitz; A Hermanowski-Vosatka; JI Weitz; A Solms; S Schmidt; M Patel; G Peters,2020,Atrial fibrillation; Drug monitoring; Pharmacokinetics; Randomized controlled trial; Rivaroxaban,0.7475712895393372,PMC7293978,PK - None | Study Population - None
115,29928148,Erratum: A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum.,,2018,,0.7452776432037354,PMC6001736,
116,23466964,Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.,PC Wong; A White; J Luettgen,2013,,0.7431735396385193,,
117,31583609,Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.,F Stader; H Kinvig; MA Penny; M Battegay; M Siccardi; C Marzolini,2020,,0.7358614206314087,,
118,17100983,"Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.",D Kubitza; M Becka; W Mueck; M Zuehlsdorf,2007,,0.731166422367096,PMC2203251,
119,19071881,Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.,BI Eriksson; DJ Quinlan; JI Weitz,2009,,0.7305321097373962,,
120,30002384,Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.,AL Sennesael; N Panin; C Vancraeynest; L Pochet; A Spinewine; V Haufroid; L Elens,2018,,0.7273814678192139,PMC6043481,
121,25880707,Of men and meals.,J Beyer-Westendorf; G Siegert,2015,anticoagulant drugs; deep vein thrombosis; fasting; recurrence; rivaroxaban; venous thromboembolism,0.721951961517334,,
122,32920985,Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.,J Nakagawa; T Kinjo; M Iizuka; K Ueno; H Tomita; T Niioka,2021,"
ABCB1
; 
ABCG2
; 
CYP2J2*7
; 
CYP3A5*3
; rivaroxaban",0.7217328548431396,,
123,19066002,New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.,LC Borris,2008,,0.7057409286499023,PMC2597756,PK - None | Study Population - None
124,22177763,[Pharmacologic heterogeneity of new anticoagulants].,MM Samamaa; J Conard; C Flaujac; S Combe; MH Horellou,2011,,0.7010247707366943,,
125,27116356,"Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.",WL Zhang; D Lou; DT Zhang; Y Zhang; HJ Huang,2016,Apixaban; Edoxaban; Pharmacokinetics; Plasma; Rivaroxaban; UPLC–MS/MS,0.6931759715080261,,
126,28074293,[Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?],M Buerke; HM Hoffmeister,2017,Atrial fibrillation; Hemorrhage; Surgery; Venous thromboembolism; direct thrombin antagonist Factor Xa inhibitors,0.667988121509552,,
127,34366862,Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation.,RJ Xu; T Ling; H Tang; WH Ge; Q Jiang,2021,drug drug interaction; physiologically based pharmacokinetic; prosthetic joint infection; rifampin; rivaroxaban,0.6509581804275513,PMC8342882,
128,23337693,Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients.,M Kaneko; T Tanigawa; K Hashizume; M Kajikawa; M Tajiri; W Mueck,2013,,0.6473278403282166,,
129,28844423,Dosing-time-dependent effect of rivaroxaban on coagulation activity in rats.,Y Fujiwara; H Ando; K Ushijima; M Horiguchi; C Yamashita; A Fujimura,2017,Chronotherapy; Circadian rhythm; Coagulation factors; Direct oral anticoagulants; Rivaroxaban,0.645283579826355,,
130,30698331,An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.,M Cini; C Legnani; S Testa; A Tripodi; B Cosmi; G Palareti,2019,apixaban; edoxaban; enoxaparin; interference; rivaroxaban,0.6286877393722534,PMC6850445,
131,32053549,"Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry.",M Zhang; GA Moore; PKL Chin,2020,,0.6162021160125732,,
132,29977164,Pharmacological properties of betrixaban.,MV Huisman; FA Klok,2018,Betrixaban; Direct oral anticoagulant; Medically ill; Pharmacokinetics; Thromboprophylaxis; Venous thromboembolism,0.6147101521492004,PMC6016700,PK - None | Study Population - None
133,33030266,Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.,Y Otsuka; MP Choules; PL Bonate; K Komatsu,2020,,0.6081962585449219,PMC7679072,PK - None | Study Population - None
134,25280819,Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban.,H Ishihara; H Torii; H Imoto; F Oka; H Sadahiro; M Suzuki,2014,Anticoagulant therapy; cardiogenic embolism; cerebral infarction; thrombolysis; tissue plasminogen activator,0.6023523211479187,,
135,22958812,Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.,IY Gong; SE Mansell; RB Kim,2013,,0.5998252034187317,,
136,33432589,Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation.,M Bendayan; V Mardigyan; D Williamson; A Chen-Tournoux; S Eintracht; L Rudski; E MacNamara; M Blostein; M Afilalo; J Afilalo,2021,anticoagulation; atrial fibrillation; frailty; pharmacokinetics; sarcopenia,0.5976929664611816,,
137,29260434,Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach.,TA Wani; H AlRabiah; AH Bakheit; MA Kalam; S Zargar,2017,Bovine serum albumin; Fluorescence; Human serum albumin; Quenching; Rivaroxaban,0.5953659415245056,PMC5736510,
138,30235484,Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels.,M Sacco; S Lancellotti; F Berruti; A Arcovito; A Bellelli; T Ricciardelli; I Autiero; L Cavallo; R Oliva; R De Cristofaro,2018,,0.5897830128669739,,
139,29287144,Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.,S Metre; S Mukesh; SK Samal; M Chand; AT Sangamwar,2018,Caco-2 permeability; P-gp inhibition; apparent solubility; pharmacokinetics; polymeric amorphous solid dispersion; rivaroxaban,0.5858665108680725,,
140,33963483,Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.,N Bernaitis; T Badrick; S Anoopkumar-Dukie,2021,Anticoagulants; Apixaban; Dabigatran; Drug interactions; Rivaroxaban; Warfarin,0.584841787815094,,
141,30918237,Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.,M Suwa; I Morii; M Kino,2019,Anticoagulation monitoring; Apixaban; Atrial fibrillation; Off-label dosing; Rivaroxaban,0.5838094353675842,,
142,34155947,The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels.,AC Scheibner; C Franco-Martinez; E Kincaide; R Hall; C Long,2021,direct oral anticoagulants; pharmacokinetics; solid organ transplant; tacrolimus,0.5821174383163452,,
143,29593860,Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients.,HL Forbes; TM Polasek,2017,DOACs; bleeding; direct oral anticoagulants; drug–drug interactions; selective serotonin reuptake inhibitors,0.5724737644195557,PMC5865464,
144,31931327,Development and validation of a novel UPLC-MS/MS method for quantification of delafloxacin in plasma and aqueous humour for pharmacokinetic analyses.,M Iqbal; E Ezzeldin; RN Herqash; MK Anwer; F Azam,2020,Aqueous humour; Delafloxacin; Nanoparticles; UPLC-MS/MS,0.563256025314331,,
145,32323191,Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.,A Solms; S Willmann; I Reinecke; TE Spiro; G Peters; JI Weitz; W Mueck; D Garmann; S Schmidt; L Zhang; KAA Fox; SD Berkowitz,2020,Drug monitoring; Exposure–response; Rivaroxaban; Venous thromboembolism,0.5623495578765869,PMC7293979,PK - None | Study Population - None
146,29475063,"Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.",X Hu; Y Xiao; C Yu; Y Zuo; W Yang; X Wang; B Gu; J Li,2018,Anticoagulant; Blood coagulation; Factor Xa inhibitor; Hemostasis; Thrombosis,0.5615918040275574,,
147,30719631,Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.,KM Miller; MJ Brenner,2019,,0.5560784339904785,,
148,28671072,Anticoagulant activity of oral rivaroxaban in healthy dogs.,B Conversy; MC Blais; M Dunn; C Gara-Boivin; JRE Del Castillo,2017,Anticoagulant; Canine; Rivaroxaban; Thromboelastography,0.5432614088058472,,
149,32323190,Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.,I Reinecke; A Solms; S Willmann; TE Spiro; G Peters; JI Weitz; W Mueck; D Garmann; S Schmidt; L Zhang; KAA Fox; SD Berkowitz,2020,Drug monitoring; Exposure–response; Rivaroxaban; Venous thromboembolism,0.5370674729347229,PMC7293976,PK - None | Study Population - None
150,27747723,Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy.,CE Corallo; L Grannell; H Tran,2015,,0.5353925824165344,PMC5005638,
151,30720378,Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases.,DMN Abouhussein; D Bahaa El Din Mahmoud; E Mohammad F,2019,Rivaroxaban; anticoagulant; paediatrics; self nanoemulsifying system; venous thromboembolism,0.5297566056251526,,
152,29055248,Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy.,KI Foerster; A Huppertz; OJ Müller; T Rizos; L Tilemann; WE Haefeli; J Burhenne,2018,Anticoagulation therapy; Direct oral anticoagulant; Human plasma; Solid phase extraction; Tandem mass spectrometry; Ultra-performance liquid chromatography,0.5268534421920776,,
153,31682296,Impact of rivaroxaban plasma concentration on perioperative red blood cell loss.,A Kaserer; GE Kiavialaitis; J Braun; A Schedler; P Stein; J Rössler; DR Spahn; JD Studt,2020,,0.5261346101760864,,
154,32461505,Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation.,W Wongcharoen; P Pacharasupa; L Norasetthada; S Gunaparn; A Phrommintikul,2020,Anti-factor Xa activity; Direct Xa inhibitor; Direct oral anticoagulant; Non-vitamin K oral anticoagulant; Rivaroxaban,0.5213460326194763,,
155,32466800,Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study.,Y Li; L Du; X Tang; Y Chen; D Mei,2020,Concentration monitoring; DVT; Rivaroxaban; UPLC-MS/MS,0.5211150050163269,PMC7257180,
156,32267996,Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients.,R Konicki; D Weiner; J Herbert Patterson; D Gonzalez; A Kashuba; YC Cao; AK Gehi; P Watkins; JR Powell,2020,,0.5071632266044617,PMC7359950,PK - None | Study Population - None
157,23535530,Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.,S Lam,2013,,0.5052810311317444,,
158,29999801,Rivaroxaban.,,2006,"Rivaroxaban, Xarelto, UNII-9NDF7JZ4M3, BAY 59-7939, 9NDF7JZ4M3, HSDB 8149, BAY59-7939, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide",0.6699737906455994,,
159,34498156,Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone.,"Potere, Nicola, Candeloro, Matteo, Porreca, Ettore, Marinari, Stefano, Federici, Camilla, Auciello, Raffaella, Di Nisio, Marcello",2022,"Anticoagulants, Apixaban, COVID-19, Dexamethasone, Embolism, Rivaroxaban, Thrombosis",0.8071208596229553,PMC8425464,PK - None | Study Population - Table 1
160,34637608,"Bioequivalence and Food Effect Assessment of 2 Rivaroxaban Formulations in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, and 4-Period Crossover Study.","Tao, Ye, Jiang, Xin, Shi, Ping, Liu, Yanping, Lin, Pingping, Liu, Shuqin, Li, Ting, Ma, Yaping, Gao, Xiaomeng, Cao, Yu",2022,"bioequivalence, healthy subjects, pharmacokinetics, rivaroxaban",0.7215362191200256,,
161,35000196,Case series of massive direct oral anticoagulant ingestion-Treatment and pharmacokinetics data.,"Delrue, Maxime, Chevillard, Lucie, Stepanian, Alain, Dragoni, Alessandra, Camoin-Jau, Laurence, Voicu, Sebastien, Malissin, Isabelle, Deye, Nicolas, Gainnier, Marc, Siguret, Virginie, Megarbane, Bruno",2022,"Netherlands, apixaban, dabigatran, direct oral anticoagulant, pharmacokinetic modelling, poisoning",0.6689993143081665,,
162,35316848,Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.,"Zhang, Feilong, Chen, Xuehai, Wu, Tingting, Huang, Nianxu, Li, Li, Yuan, Dongdong, Xiang, Jing, Wang, Na, Chen, Wenjun, Zhang, Jinhua",2022,,0.651355504989624,,
163,35370683,A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation.,"Zhao, Nan, Liu, Zhiyan, Xie, Qiufen, Wang, Zhe, Sun, Zhongyi, Xiang, Qian, Cui, Yimin",2022,"Chinese, PK/PD, anti-xa activity, bleeding, population pharmacokinetics, prothrombin time, rivaroxaban",0.9635006785392761,PMC8971662,PK - TABLE 2 | Study Population - TABLE 1
164,35386137,"Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults.","Hill, Kevin, Sucha, Ewa, Rhodes, Emily, Bota, Sarah, Hundemer, Gregory L, Clark, Edward G, Canney, Mark, Harel, Ziv, Wang, Tzu-Fei, Carrier, Marc, Wijeysundera, Harindra C, Knoll, Greg, Sood, Manish M",2022,,0.5975558757781982,PMC8978070,
165,35401180,Changes in the Gut Microbiota May Affect the Clinical Efficacy of Oral Anticoagulants.,"Chen, Wenjun, Qian, Jiafen, Fu, Jinglan, Wu, Tingting, Lv, Meina, Jiang, Shaojun, Zhang, Jinhua",2022,"P-gp, bioavailability, gut microbiota, liver drug enzymes, oral anticoagulants",0.5424755811691284,PMC8989842,"PK - TABLE 2, TABLE 3, TABLE 4 | Study Population - None"
166,35455642,Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.,"Lenoir, Camille, Terrier, Jean, Gloor, Yvonne, Gosselin, Pauline, Daali, Youssef, Combescure, Christophe, Desmeules, Jules Alexandre, Samer, Caroline Flora, Reny, Jean-Luc, Rollason, Victoria",2022,"DOACs, metabolism, personalized medicine, pharmacogenomics, phenotype",0.7448604106903076,PMC9028714,PK - None | Study Population - Table 1
167,35467325,Amalgamation of solid dispersion and melt adsorption techniques for augmentation of oral bioavailability of novel anticoagulant rivaroxaban.,"Shah, Pranav J, Patel, Milan P, Shah, Jigar, Nair, Anroop B, Kotta, Sabna, Vyas, Bhavin",2022,"Dissolution, Factorial design, Pharmacodynamics, Pharmacokinetics, Rivaroxaban, Solid dispersion adsorbate",0.5445941686630249,,
168,35504629,Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients.,"Esmaeili, Tayebeh, Rezaee, Mahmood, Abdar Esfahani, Morteza, Davoudian, Azadeh, Omidfar, Dariush, Rezaee, Saeed",2022,"anti-factor Xa activity, population pharmacokinetics/pharmacodynamics, rivaroxaban",0.5591141581535339,,
169,35510948,"A Single-blind, Randomized, Single-dose, Two-sequence, Two-period, Crossover Study to Assess the Bioequivalence between Two Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Mexican Volunteers.","Genis-Najera, Luis, Sanudo-Maury, Maria Elena, Moquete, Trinifer",2022,"anticoagulants, bioequivalence, pharmacokinetics, rivaroxaban, safety",0.6194500923156738,PMC9321699,"PK - Table 2, Table 3 | Study Population - Table 1"
170,35517810,Single and Repeated Doses of EGb 761((R)) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects.,"Hoerr, Robert, Zimmermann, Andrea, Seitz, Friedeborg, Dienel, Angelika",2022,"EGb 761(R), Ginkgo biloba extract, drug-drug interaction, healthy subjects, pharmacodynamics, pharmacokinetics, rivaroxaban",0.9563889503479004,PMC9065292,"PK - TABLE 1, TABLE 2 | Study Population - None"
171,35663355,"Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs.","Meng, Yuanyuan, Tan, Fangyun, Yao, Jiaxin, Cui, Yanan, Feng, Yumiao, Li, Zhiping, Wang, Yuli, Yang, Yang, Gong, Wei, Yang, Meiyan, Kong, Xiaolong, Gao, Chunsheng",2022,"Beagle dogs, Cocrystals, Dissolution, Permeation, Pharmacokinetics, Rivaroxaban, Solubility",0.9344624876976013,PMC9160491,PK - Table. 1 | Study Population - None
172,35960493,The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation.,"Sychev, Dmitry, Ostroumova, Olga, Cherniaeva, Marina, Shakhgildian, Nataliia, Mirzaev, Karin, Abdullaev, Sherzod, Denisenko, Natalia, Sozaeva, Zhannet, Kachanova, Anastasia, Gorbatenkova, Svetlana, Shastina, Vera",2022,"ABCB1 (rs1045642), ABCB1 (rs4148738), Elderly patients, Nonvalvular atrial fibrillation, Pharmacogenetics, Rivaroxaban",0.6135547757148743,,
173,36003022,Determination of rivaroxaban in rat plasma by ultra-high-performance liquid chromatography-Q-Orbitrap high-resolution mass spectrometry and its application to a pharmacokinetic study.,"Qian, Jing, Gu, Shun-Zhong, Yan, Yong-Jin",2022,"UHPLC-Q-Orbitrap HRMS, pharmacokinetic study, rivaroxaban",0.5000550150871277,,
174,36015370,Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation.,"Singkham, Noppaket, Phrommintikul, Arintaya, Pacharasupa, Phongsathon, Norasetthada, Lalita, Gunaparn, Siriluck, Prasertwitayakij, Narawudt, Wongcharoen, Wanwarang, Punyawudho, Baralee",2022,"Thai patient, atrial fibrillation, direct oral anticoagulants, population pharmacokinetic, rivaroxaban",0.9802780747413635,PMC9414338,PK - Table 2 | Study Population - Table 1
175,36071847,Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp.,"Zhao, Tingting, Li, Xuening, Chen, Yanwei, Du, Jie, Chen, Xiaodong, Wang, Dalong, Wang, Liyan, Zhao, Shan, Wang, Changyuan, Meng, Qiang, Sun, Huijun, Liu, Kexin, Wu, Jingjing",2022,"BCRP, CYP2J2, CYP3A4, P-gp, drug-drug interaction, rivaroxaban",0.8771148324012756,PMC9441481,"PK - TABLE 5, TABLE 6 | Study Population - None"
176,36201149,Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.,"Alalawneh, Majdoleen, Awaisu, Ahmed, Rachid, Ousama",2022,,0.677055299282074,PMC9734246,
177,36506510,Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients.,"Campos-Staffico, Alessandra M, Dorsch, Michael P, Barnes, Geoffrey D, Zhu, Hao-Jie, Limdi, Nita A, Luzum, Jasmine A",2022,"DOAC, anticoagulation, atrial fibrillation, bleeding, pharmacogenetics",0.8834978342056274,PMC9730333,"PK - None | Study Population - TABLE 1, TABLE 2"
178,36683488,Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.,"Leow, Jacqueline Wen Hui, Ang, Xiao Jun, Chan, Eric Chun Yong",2023,"N-desbutyldronedarone, dronedarone, drug-drug interactions, physiologically based pharmacokinetic modelling, rivaroxaban",0.7315906882286072,,
179,36720501,Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child).,"Hermann, Simon A, Mikus, Gerd, Chobanyan-Jurgens, Kristine, Gorenflo, Matthias, Ziesenitz, Victoria C",2023,"Cardiology, Pharmacology",0.5512925982475281,PMC9890763,PK - None | Study Population - None
180,36862336,Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review.,"Edwina, Angela Elma, Dia, Nada, Dreesen, Erwin, Vanassche, Thomas, Verhamme, Peter, Spriet, Isabel, Van der Linden, Lorenz, Tournoy, Jos",2023,,0.5486689209938049,,
181,36871246,Comparative pharmacokinetics of two formulations of 2.5-mg rivaroxaban in healthy Korean subjects.,"Moon, Seol Ju, Kim, Yunjeong, Kim, Sun-Young, Jeon, Ji-Young, Song, Eunji, Lim, Yeji, Kim, Min-Gul",2023,,0.9784474968910217,,
182,37026424,Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World Patients.,"Powell, J Robert, Al Qaraghuli, Farah, Fiedler-Kelly, Jill, Gonzalez, Daniel, Weiner, Daniel",2023,,0.5646699070930481,,
183,37102317,Population Pharmacokinetics of Rivaroxaban in Real-World Patients.,"Alqahtani, Saeed, Alnahdi, Jamilah, Almofada, Razan, Bin Hazza, Asma'a, Alsultan, Abdullah, Alqahtani, Farjah",2023,"anticoagulation, pharmacokinetics, population PK, rivaroxaban",0.7842878699302673,,
184,37210712,"Pharmacokinetics, Bioequivalence, and Safety Evaluation of 2 Formulations of 10-mg Rivaroxaban Tablets: A 4-Period Crossover Trial.","Zhang, Canhua, Shen, Zihan, Li, Jianhao, Wu, Yaofen, Xu, Zuoheng, Gu, Wenzhao, Jian, Jianqing, Wu, Zixing, Liu, Weixiong, Yang, Hui, Su, Jianfen",2023,"bioequivalence, healthy Chinese volunteers, pharmacokinetics, rivaroxaban, safety",0.988933801651001,,
185,37242468,Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug-Drug Interaction between Rivaroxaban and Carbamazepine in Humans.,"Ngo, Lien Thi, Yun, Hwi-Yeol, Chae, Jung-Woo",2023,"allometric scaling, carbamazepine, drug-drug interaction, population pharmacokinetics, rivaroxaban",0.963483452796936,PMC10223163,PK - Table 2 | Study Population - None
186,37385211,NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers.,"Villapalos-Garcia, Gonzalo, Zubiaur, Pablo, Ochoa, Dolores, Soria-Chacartegui, Paula, Navares-Gomez, Marcos, Matas, Miriam, Mejia-Abril, Gina, Casajus-Rey, Ana, Campodonico, Diana, Roman, Manuel, Martin-Vilchez, Samuel, Candau-Ramos, Carmen, Aldama-Martin, Marina, Abad-Santos, Francisco",2023,"Direct oral anticoagulants, NAT2, Pharmacogenetics, Rivaroxaban",0.5756795406341553,,
187,37542618,Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation.,"Li, Xiaoye, Gu, Zhichun, Wang, Zi, Xu, Qing, Ma, Chunlai, Lv, Qianzhou",2023,"Atrial fibrillation, CYP3A4/5, Pharmacodynamics, Pharmacogenetics, Pharmacokinetics, Rivaroxaban",0.9632535576820374,,
188,37568371,Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight-Pilot Study.,"Wolowiec, Lukasz, Kusiak, Mateusz, Budzynski, Jacek, Wolowiec, Anna, Jasniak, Albert, Wicinski, Michal, Pedrycz-Wieczorska, Agnieszka, Rogowicz, Daniel, Grzesk, Grzegorz",2023,"atrial fibrillation, body weight, direct oral anticoagulants (DOACs), obesity, therapeutic drug monitoring",0.5297570824623108,PMC10419712,PK - None | Study Population - Table 2
189,37664781,Effects of rivaroxaban on myocardial mitophagy in the rat heart.,"Gencpinar, Tugra, Bilen, Cagatay, Kemahli, Baris, Kacar, Kivanc, Akokay, Pinar, Bayrak, Serdar, Erdal, Cenk",2023,"Anticoagulation, apoptosis, cardiac ischemia, mitophagy, rivaroxaban.",0.6132223606109619,PMC10472476,PK - None | Study Population - None
190,37740607,Effect of a High-Fat Diet on the Pharmacokinetics and Safety of Rivaroxaban in Healthy Chinese Subjects.,"Sun, Xue, Song, Haojing, Liu, Huan, Qiu, Bo, Ding, Congyang, Hu, Yiting, Bai, Wanjun, Dong, Zhanjun",2024,"food, high fat, pharmacokinetics, rivaroxaban, safety",0.9221818447113037,,
191,37763139,Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy.,"Baturina, Olga, Chashkina, Maria, Andreev, Denis, Mirzaev, Karin, Bykova, Alexandra, Suvorov, Alexandr, Yeryshova, Daria, Suchkova, Svetlana, Sychev, Dmitry, Syrkin, Abram",2023,"acute coronary syndrome, atrial fibrillation, clopidogrel, combined antithrombotic therapy, dual antiplatelet therapy, major bleeding, rivaroxaban, triple antiplatelet therapy",0.898442268371582,PMC10532904,"PK - None | Study Population - Table 1, Table 4"
192,37860116,"In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban.","Wang, Zhi, Li, Ying, He, Xueru, Fu, Yuhao, Li, Yajing, Zhou, Xin, Dong, Zhanjun",2023,"UPLC-MS/MS, almonertinib, apixaban, drug-drug interactions, pharmacokinetics, rivaroxaban",0.9386744499206543,PMC10582335,"PK - TABLE 6, TABLE 7, TABLE 8 | Study Population - None"
193,37950768,Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.,"Li, Ze, Yang, Siyu, Hua, Zixin, Lu, Yanxia, Li, Xingang",2024,"Deep vein thrombosis, Dosing guideline, Estimated glomerular filtration rate, Population pharmacokinetics, Rivaroxaban",0.6899781227111816,,
194,38000647,An extension of biorelevant fed-state dissolution tests to clinical pharmacokinetics - A study on gastrointestinal factors influencing rivaroxaban exposure and efficacy in atrial fibrillation patients.,"Romanski, Michal, Giebultowicz, Joanna, Gniazdowska, Elzbieta, Piotrowski, Roman, Zuk, Anna, Kulakowski, Piotr, Paszkowska, Jadwiga, Myslitska, Daria, Sczodrok, Jaroslaw, Garbacz, Grzegorz, Danielak, Dorota",2024,"Atrial fibrillation, biopredictive dissolution, Fed state, In-vitro-in-vivo modeling, Pharmacotherapy efficiency, Population pharmacokinetics",0.5872756838798523,,
195,38152435,Expedited surgery does not increase transfusion rates for patients with geriatric hip fracture taking factor Xa inhibitors.,"Wang, Juntian, Nilssen, Paal, Stone, Julia, Breda, Kathleen, Little, Milton, Moon, Charles, Lin, Carol",2023,"anticoagulant, apixaban, fracture, geriatrics, hip, rivaroxaban, trauma",0.525343656539917,PMC10750454,
196,38393578,"Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.","Rohr, Brit S, Krohmer, Evelyn, Foerster, Kathrin I, Burhenne, Jurgen, Schulz, Martin, Blank, Antje, Mikus, Gerd, Haefeli, Walter E",2024,,0.698092520236969,PMC11052790,
197,38399378,Novel Thiourea and Oxime Ether Isosteviol-Based Anticoagulants: MD Simulation and ADMET Prediction.,"Gackowski, Marcin, Jedrzejewski, Mateusz, Medicharla, Sri Satya, Kondabala, Rajesh, Madriwala, Burhanuddin, Madra-Gackowska, Katarzyna, Studzinska, Renata",2024,"ADMET prediction, activated blood coagulation factor X (FXa) inhibitors, anticoagulants, isosteviol, molecular dynamics (MD) simulation, thrombosis",0.5123664140701294,PMC10892930,PK - None | Study Population - None
198,38553322,The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study.,"Liu, Zhiyan, Xie, Qiufen, Zhao, Xia, Tan, Yunlong, Wang, Wenping, Cao, Yu, Wei, Xiaohua, Mu, Guangyan, Zhang, Hanxu, Zhou, Shuang, Wang, Xiaobin, Cao, Ying, Li, Xin, Chen, Song, Cao, Duanwen, Cui, Yimin, Xiang, Qian",2024,"Gene polymorphism, Pharmacodynamics, Pharmacokinetics, Rivaroxaban",0.8629541397094727,,
199,38633324,Managing venous thrombosis in a pediatric patient with short bowel and congenital nephrotic syndromes: a case report emphasizing rivaroxaban level monitoring.,"Bosch-Schips, Marc, Artaza, Gonzalo, Hernandez-Mata, Carlos, Perez Beltran, Victor, Cabello Ruiz, Vanessa, Olivera Sumire, Pavel",2024,"anticoagulation, congenital nephrotic syndrome, direct action anticoagulants, short bowel syndrome, thrombosis",0.9311981201171875,PMC11021599,
200,38847347,Pharmacokinetics of single-dose rivaroxaban under fed state in obese vs. non-obese subjects: An open-label controlled clinical trial (RIVOBESE-PK).,"Alalawneh, Majdoleen, Awaisu, Ahmed, Abdallah, Ibtihal, Elewa, Hazem, Danjuma, Mohammed, Matar, Kamal M, ElKashlan, Akram M, Elshayep, Yasser, Ibrahim, Fathy, Rachid, Ousama",2024,,0.905250608921051,PMC11157419,"PK - TABLE 2, TABLE 3 | Study Population - TABLE 1"
201,38958362,ABCG2 polymorphism and rivaroxaban pharmacokinetics in healthy individuals after a single dose.,"Santos, A F Dos, Francisco, Q A S, Nunes, J B, Colombo, F A, Boralli, V B",2024,,0.8856068253517151,PMC11221861,"PK - Table 2, Table 4 | Study Population - Table 1"
202,39136405,Exposure Matching-Based Pediatric Dose Selection for Drugs with Renal Excretion - Lessons Learned from Pediatric Development of Direct Oral Anticoagulants.,"Zou, Peng, Leil, Tarek A",2024,,0.7421709895133972,,
203,39139554,"Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial.","Mittal, Prabal, Gafoor, Rafael, Sayar, Zara, Efthymiou, Maria, Tohidi-Esfahani, Ibrahim, Appiah-Cubi, Stella, Arachchillage, Deepa J, Atkinson, David, Bordea, Ekaterina, Cardoso, M Jorge, Caverly, Emilia, Chandratheva, Arvind, Chau, Marisa, Freemantle, Nick, Gates, Carolyn, Ja Ger, H Rolf, Kaul, Arvind, Mitchell, Chris, Nguyen, Hanh, Packham, Bunis, Paskell, Jaye, Patel, Jignesh P, Round, Chris, Sanna, Giovanni, Zaidi, Abbas, Werring, David J, Isenberg, David, Cohen, Hannah",2024,"antiphospholipid syndrome, ischemic stroke, rivaroxaban, thrombosis, warfarin",0.6714280247688293,PMC11321294,PK - None | Study Population - None
204,39204351,Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation.,"Ding, Huamin, Wang, Zi, Wang, Jia, Yao, Yao, Zhang, Chi, Lin, Houwen, Zhou, Yong, Gu, Zhichun, Lv, Qianzhou, Li, Xiaoye",2024,"DDI, PK/PD, amiodarone, bleeding events, rivaroxaban",0.9590433239936829,PMC11359575,PK - None | Study Population - Table 1
205,39218046,"In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants.","Jin, Shasha, Paludetto, Marie-Noelle, Kurkela, Mika, Kahma, Helina, Neuvonen, Mikko, Xiang, Xiaoqiang, Cai, Weimin, Backman, Janne T",2024,"CYP time-dependent inhibition, CYP-mediated drug-drug interaction, Direct oral anticoagulants, Kinase inhibitors, Mechanistic static and physiologically-based pharmacokinetic models, Warfarin",0.7033974528312683,,
206,39352531,Effect of Danhong injection on pharmacokinetics and pharmacodynamics of rivaroxaban in rats.,"Yin, Weihong, Li, Jiao, Han, Zhaoyang, Wang, Siwen, Wu, Fan, Yu, Chao, Yan, Xueying, Cui, Mingyu",2024,"CYP3A2, Danhong injection, Herb-drug interactions, Pharmacodynamics, Pharmacokinetics, Rivaroxaban",0.9406437277793884,,
